Jazz Pharmaceuticals JAZZ Non-deductible AIPR&D
Non-deductible AIPR&D at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-deductible aipr&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-deductible aipr&d?
- Jazz Pharmaceuticals (JAZZ) reported non-deductible aipr&d of -29.8% in Q4 2025.
- What does non-deductible aipr&d mean?
- The amount of R&D acquisition costs that are not tax-deductible.
- How do you interpret non-deductible aipr&d?
- An increase indicates higher non-deductible R&D spending, which increases the effective tax rate and reduces after-tax cash flow.
- How does non-deductible aipr&d compare across companies?
- Common in biopharma firms that frequently acquire early-stage pipelines; peers often disclose this in tax rate reconciliations.